Drug Cost Disruption: Direct Generic Access Can Save Consumers Billions

Hubwonk host Joe Selvaggi talks with Dr. Hussain Lalani about his recently published research on the potential for more than $3 billion in savings were Medicare to use Mark Cuban’s new direct-to-consumer drug company to purchase generics.


Dr. Hussain Lalani is a Primary Care Physician at Brigham and Women’s Hospital, Fellow at Harvard Medical School and the Program on Regulation, Therapeutics, and Law (PORTAL), and a part-time student in the Masters of Science in Health Policy and Management and the Harvard T.H. Chan School of Public Health. He is a first-generation American, born and raised in Dallas, and practices Internal Medicine at the Phyllis Jen Center providing comprehensive primary health care to adults managing chronic diseases, behavioral health, and preventive screenings. He is passionate about ensuring affordable access to equitable healthcare for all, with a current focus on prescription drug pricing policy as a lens into the complexities of health care delivery and policy. Dr. Lalani’s work has been published broadly in the JAMA Internal Medicine, JAMA Network Open, JAMA Cardiology, Annals of Internal Medicine, and the American Journal of Managed Care. He is the Co-Founder of This Is Our Shot and VacunateYa, a national grassroots social media organization that elevates the voices of trusted medical professionals to build healthier communities and combat health misinformation. Visit www.thisisourshot.info and www.vacunateya.com to learn more.

Subscribe to HubWonk in Apple Podcasts (and leave a 5-star review, please!), or by RSS feed. For all our podcasts in one place, subscribe to the Ricochet Audio Network Superfeed in Apple Podcasts or by RSS feed.